Rune Labs Raises $12M in Funding to Propel Parkinson’s Innovations
Precision neurology company Rune Labs has secured $12 million in a strategic funding round, propelling its total capital to over $42 million. Nexus NeuroTech Ventures led the investment to advance the adoption of Rune Labs’ innovative technologies focused on Parkinson’s disease.
Rune Labs, a cutting-edge software and data analytics company, has gained significant support for its groundbreaking initiatives. The company’s flagship StrivePD software has rapidly become the most widely used tool among Parkinson’s patients and clinicians. Rune Labs has now entered into a strategic partnership with Nexus NeuroTech Ventures. The partnership aims to leverage modern AI tools for patient support and to advance Parkinson’s understanding and treatment. The $12 million funding injection will propel Rune Labs into a new era of personalized care for Parkinson’s disease.
Rune Labs’ StrivePD software ecosystem received FDA 510(k) clearance in 2022, allowing it to collect crucial patient symptom data through measurements made by Apple Watch. The company has also forged partnerships with leading innovators in neuroscience, including collaborations with BlueRock Therapeutics and Aspen Neuroscience. These collaborations aim to assess symptom activity in Parkinson’s clinical trials using Rune Lab’s StriveStudy clinical development platform.
Future Aspirations
Rune Labs distinguishes itself by providing actionable data to Parkinson’s patients, fostering engagement with the StrivePD tool. The company’s unique approach centers around delivering personalized insights at scale, aided by generative AI tools. As Benjamin Stecher, Chair of the Patient Advisory Board at Rune Labs, attests,
“StrivePD has given far more accurate readouts of my symptoms to my doctors, enabling a more precise management plan.”
The company’s commitment to advancing technology is crucial in addressing the pressing need for novel therapies to combat Parkinson’s disease.
Rune Labs’ successful funding round not only signifies a financial milestone but also signals a continued commitment to advancing Parkinson’s technologies. As the company propels forward, the intersection of AI, precision medicine, and strategic collaborations will undoubtedly play a pivotal role in shaping the future of Parkinson’s care.
